Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B−/− (Wilson disease) mice

Wilson disease (WD) is a hepatoneurological disorder caused by mutations in the copper-transporter, ATP7B. Copper accumulation in the liver is a hallmark of WD. Current therapy is based on copper chelation, which decreases the manifestations of liver disease, but often worsens neurological symptoms....

Full description

Saved in:
Bibliographic Details
Main Authors: Hamilton, James P. (Author) , Koganti, Lahari (Author) , Muchenditsi, Abigael (Author) , Pendyala, Venkata S. (Author) , Huso, David (Author) , Hankin, Joseph (Author) , Murphy, Robert C. (Author) , Huster, Dominik (Author) , Merle, Uta (Author) , Mangels, Christopher (Author) , Yang, Nan (Author) , Potter, James J. (Author) , Mezey, Esteban (Author) , Lutsenko, Svetlana (Author)
Format: Article (Journal)
Language:English
Published: 2016
In: Hepatology
Year: 2015, Volume: 63, Issue: 6, Pages: 1828-1841
ISSN:1527-3350
DOI:10.1002/hep.28406
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/hep.28406
Verlag, lizenzpflichtig, Volltext: https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.28406
Get full text
Author Notes:James P. Hamilton, Lahari Koganti, Abigael Muchenditsi, Venkata S. Pendyala, David Huso, Joseph Hankin, Robert C. Murphy, Dominik Huster, Uta Merle, Christopher Mangels, Nan Yang, James J. Potter, Esteban Mezey, and Svetlana Lutsenko
Description
Summary:Wilson disease (WD) is a hepatoneurological disorder caused by mutations in the copper-transporter, ATP7B. Copper accumulation in the liver is a hallmark of WD. Current therapy is based on copper chelation, which decreases the manifestations of liver disease, but often worsens neurological symptoms. We demonstrate that in Atp7b−/− mice, an animal model of WD, liver function can be significantly improved without copper chelation. Analysis of transcriptional and metabolic changes in samples from WD patients and Atp7b−/− mice identified dysregulation of nuclear receptors (NRs), especially the liver X receptor (LXR)/retinoid X receptor heterodimer, as an important event in WD pathogenesis. Treating Atp7b−/− mice with the LXR agonist, T0901317, ameliorated disease manifestations despite significant copper overload. Genetic markers of liver fibrosis and inflammatory cytokines were significantly decreased, lipid profiles normalized, and liver function and histology were improved. Conclusions: The results demonstrate the major role of an altered NR function in the pathogenesis of WD and suggest that modulation of NR activity should be explored as a supplementary approach to improving liver function in WD. (Hepatology 2016;63:1828-1841)
Item Description:First published: 17 December 2015
Gesehen am 30.09.2020
Physical Description:Online Resource
ISSN:1527-3350
DOI:10.1002/hep.28406